Showing results (21-30 of 76) with videos related to

Sort By:
Pageof 8
The American Journal of Tropical Medicine and Hygiene|July 14, 2006
Phase 1 safety and immunogenicity trial of malaria vaccine RTS,S/AS02A in adults in a hyperendemic region of western KenyaJosé A Stoute, D Gray Heppner, Carl J Mason, et al.
Vaccine|June 21, 2014
Sequential Phase 1 and Phase 2 randomized, controlled trials of the safety, immunogenicity and efficacy of combined pre-erythrocytic vaccine antigens RTS,S and TRAP formulated with AS02 Adjuvant System in healthy, malaria naïve adultsKent E Kester, D Gray Heppner, Philippe Moris, et al.
The American Journal of Tropical Medicine and Hygiene|May 25, 2004
Safety and immunogenicity of rts,s+trap malaria vaccine, formulated in the as02a adjuvant system, in infant rhesus monkeysDouglas S Walsh, Sathit Pichyangkul, Montip Gettayacamin, et al.
Plos Clinical Trials|July 28, 2006
RTS,S/AS02A malaria vaccine does not induce parasite CSP T cell epitope selection and reduces multiplicity of infectionSonia Enosse, Carlota Dobaño, Diana Quelhas, et al.
Vaccine|September 15, 2004
Pre-clinical evaluation of the malaria vaccine candidate P. falciparum MSP1(42) formulated with novel adjuvants or with alumSathit Pichyangkul, Montip Gettayacamin, R Scott Miller, et al.
Plos One|November 17, 2010
Safety, immunogenicity and duration of protection of the RTS,S/AS02(D) malaria vaccine: one year follow-up of a randomized controlled phase I/IIb trialPedro Aide, John J Aponte, Montse Renom, et al.
Plos One|October 28, 2009
A randomized trial assessing the safety and immunogenicity of AS01 and AS02 adjuvanted RTS,S malaria vaccine candidates in children in GabonBertrand Lell, Selidji Agnandji, Isabelle von Glasenapp, et al.
Plos One|November 20, 2009
Impact of RTS,S/AS02(A) and RTS,S/AS01(B) on genotypes of P. falciparum in adults participating in a malaria vaccine clinical trialJohn N Waitumbi, Samuel B Anyona, Carol W Hunja, et al.
Vaccine|April 1, 2006
Heterologous prime-boost immunization in rhesus macaques by two, optimally spaced particle-mediated epidermal deliveries of Plasmodium falciparum circumsporozoite protein-encoding DNA, followed by intramuscular RTS,S/AS02ADouglas S Walsh, Montip Gettayacamin, Wolfgang W Leitner, et al.
Vaccine|April 15, 2008
Safety and reactogenicity profile of an adjuvanted H5N1 pandemic candidate vaccine in adults within a phase III safety trialHans C Rümke, José-María Bayas, José-Ramón de Juanes, et al.
Pageof 8